Therapeutic doses of cyproheptadine do not inhibit monoamine oxidase in man.
Cypro, a serotonin and histamine antagonist, has been shown to be a moderately potent reversible inhibitor of tissue monoamine oxidase (MAO) obtained from hamsters and rabbits. In the present study, Cypro inhibits MAO obtained from human platelets with the same potency as harmine (Ki = 5 x 10(-5) M). However, when ten normal volunteers received conventional therapeutic doses of Cypro (16 mg/day) for two days, there was no alteration in their urinary excretion of tryptamine, 5-hydroxyindoleacetic acid, 3-methoxy-4-hydroxymandelic acid, epinephrine, or norepinephrine. We conclude that, when used in conventional clinical doses, Cypro does not inhibit MAO in man.
D000328:Adult; D003533:Cyproheptadine / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004837:Epinephrine / Q000652:urine; D005260:Female; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D008297:Male; D008333:Mandelic Acids / Q000652:urine; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009638:Norepinephrine / Q000652:urine; D014363:Tryptamines / Q000652:urine
D008333:Mandelic Acids; D008996:Monoamine Oxidase Inhibitors; D014363:Tryptamines; D003533:Cyproheptadine; D006897:Hydroxyindoleacetic Acid; D009638:Norepinephrine; D004837:Epinephrine